Latest News From Lumira Ventures

Engage Therapeutics Presents Data from Part 1, Open-label Run-in of StATES Phase 2b Study of Staccato® Alprazolam at 2019 American Academy of Neurology Annual Meeting

Jennifer Schram Engage Therapeutics, Portfolio News, Press Release

8 patients with predictable generalized or focal epileptic seizures treated with Staccato alprazolam 62.5% of patients respond with the cessation of seizure activity within two minutes of therapy administration and no recurrence of seizure activity within two hours Feasibility of …

Engage Therapeutics Inc. to Present Phase 2b Data from StATES Study at 2019 American Academy of Neurology Annual General Meeting

Jennifer Schram Engage Therapeutics, Portfolio News

SUMMIT, N.J. (PRNewswire) — Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a Rapid Epileptic Seizure Termination (REST) therapy for people who experience a predictable pattern of  epileptic seizures, today announced it will present clinical data from the open label portion of …